POLBF (Poolbeg Pharma) Ending Cash Position: $10.33 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poolbeg Pharma Ending Cash Position?

Poolbeg Pharma POLBF Ending Cash Position is $10.33 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 was $10.33 Mil.

Poolbeg Pharma's quarterly Ending Cash Position increased from Dec. 2024 ($9.89 Mil) to Jun. 2025 ($13.52 Mil) but then declined from Jun. 2025 ($13.52 Mil) to Dec. 2025 ($10.33 Mil).

Poolbeg Pharma's annual Ending Cash Position declined from Dec. 2023 ($15.41 Mil) to Dec. 2024 ($9.89 Mil) but then increased from Dec. 2024 ($9.89 Mil) to Dec. 2025 ($10.33 Mil).

Poolbeg Pharma Ending Cash Position Related Terms

Poolbeg Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Ending Cash Position Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
27.86 19.72 15.41 9.89 10.33

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only 15.41 12.80 9.89 13.52 10.33

Poolbeg Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Poolbeg Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=10.473+-0.148
=10.33

Poolbeg Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=13.334+-3.009
=10.33

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $10.33 Mil mean?
Poolbeg Pharma (POLBF) has a Ending Cash Position of $10.33 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Ending Cash Position too high?
Poolbeg Pharma's current Ending Cash Position is $10.33 Mil.
How does Poolbeg Pharma's Ending Cash Position compare to VRTX and REGN?
Poolbeg Pharma's Ending Cash Position of $10.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Ending Cash Position is $10.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Ending Cash Position of $10.33 Mil. The current Ending Cash Position is $10.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Ending Cash Position is $10.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.